Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

@article{Schaffer2010LossOP,
  title={Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.},
  author={Bethany E. Schaffer and Kwon-Sik Park and Gloria Yiu and Jamie F. Conklin and ChenWei Lin and Deborah L. Burkhart and Anthony N Karnezis and E Alejandro Sweet-Cordero and Julien Sage},
  journal={Cancer research},
  year={2010},
  volume={70 10},
  pages={3877-83}
}
Small-cell lung carcinoma (SCLC) is a neuroendocrine subtype of lung cancer. Although SCLC patients often initially respond to therapy, tumors nearly always recur, resulting in a 5-year survival rate of less than 10%. A mouse model has been developed based on the fact that the RB and p53 tumor suppressor genes are mutated in more than 90% of human SCLCs. Emerging evidence in patients and mouse models suggests that p130, a gene related to RB, may act as a tumor suppressor in SCLC cells. To test… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Novel systemic therapies for small cell lung cancer.

Journal of the National Comprehensive Cancer Network : JNCCN • 2008
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…